Esophageal cancer
Conditions
Interventions
ESCC:None
Sponsors
The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1: Aged between 18 and 85 years. 2: Histopathologically confirmed diagnosis of esophageal squamous cell carcinoma. 3: Unresectable locally advanced disease (including technically unresectable tumors, patients with surgical contraindications, or those refusing surgery) classified as cT1b-4bN0M0 or cT1b-4bN+M0 ( AJCC 8th edition); or unresectable advanced disease with supraclavicular lymph node metastasis classified as cTxNxM1 ( AJCC 8th edition). 4: At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST version 1.1). 5: Karnofsky Performance Status (KPS) score >= 60. 6: Patients must have received first-line immunochemotherapy; radiotherapy is permitted, which may be administered before, during, or after immunotherapy.
Exclusion criteria
Exclusion criteria: 1: Presence of distant metastasis to solid organs or non-regional lymph nodes (excluding supraclavicular lymph node). 2: History of a second primary cancer or previous malignancy (except for radically treated papillary thyroid carcinoma, Stage I seminoma, or carcinoma in situ of the cervix). 3: Receipt of surgical resection of esophageal carcinoma. 4: Salvage immunotherapy for esophageal carcinoma that recurred after radiotherapy; or initiation of consolidative immunotherapy more than 42 days after radiotherapy completion. 5: Severe esophageal fistula or gastrointestinal hemorrhage at diagnosis, with persistent fistula or refractory bleeding despite adequate supportive treatment. 6: First-line treatment containing targeted therapeutic agents, including recombinant human endostatin injection, anlotinib, nimotuzumab injection, apatinib (except when used for treating telangiectasia), etc. 7: First-line treatment consisting of chemotherapy only, without concurrent immunotherapy or radiotherapy. 8: No radiation, chemotherapy, or immunotherapy received within 3 months after pathological diagnosis. 9: Absence of documented baseline TNM staging, or absence of baseline chest CT scan. 10: Enrollment in a double-blind clinical trial without unblinding or lack of available treatment information.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse event;Progression-free survival; | — |
Countries
China
Contacts
Public ContactDong Qian
The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China
Outcome results
None listed